$791 Million is the total value of GREAT POINT PARTNERS LLC's 42 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | New | GLOBAL BLOOD THERAPEUTICS INC | $48,439,000 | – | 1,180,000 | +100.0% | 6.12% | – |
| ZGNX | New | ZOGENIX INC | $36,460,000 | – | 1,000,000 | +100.0% | 4.61% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $35,346,000 | – | 1,657,873 | +100.0% | 4.47% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INCput | $33,142,000 | – | 200,000 | +100.0% | 4.19% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $28,077,000 | – | 1,379,700 | +100.0% | 3.55% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $26,363,000 | – | 1,850,000 | +100.0% | 3.33% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS INCput | $20,158,000 | – | 200,000 | +100.0% | 2.55% | – |
| OSMT | New | OSMOTICA PHARMACEUTICALS PLC | $11,625,000 | – | 1,500,000 | +100.0% | 1.47% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $11,164,000 | – | 1,418,489 | +100.0% | 1.41% | – |
| MLND | New | MILLENDO THERAPEUTICS INC | $10,240,000 | – | 1,288,093 | +100.0% | 1.29% | – |
| KRYS | New | KRYSTAL BIOTECH INC | $10,226,000 | – | 492,100 | +100.0% | 1.29% | – |
| AMAG | New | AMAG PHARMACEUTICALS INC | $10,097,000 | – | 664,681 | +100.0% | 1.28% | – |
| PTI | New | PROTEOSTASIS THERAPEUTICS INC | $9,867,000 | – | 3,045,423 | +100.0% | 1.25% | – |
| NVAX | New | NOVAVAX INCcall | $8,280,000 | – | 4,500,000 | +100.0% | 1.05% | – |
| SAGE | New | SAGE THERAPEUTICS INCcall | $2,491,000 | – | 26,000 | +100.0% | 0.32% | – |
| SAGE | New | SAGE THERAPEUTICS INCput | $2,491,000 | – | 26,000 | +100.0% | 0.32% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.